GGrantIndex
Sort

23,748 grants matching melanoma

Safety and Efficacy of Vemurafenib and High-Dose InterferonAlpha-2b for Advanced Melanoma

$280,797
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · P50 · FY2017 · CA

BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF

$280,788
Anton Wellstein · Georgetown University · R01 · FY2008 · CA

BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF

$280,788
Anton Wellstein · Georgetown University · R01 · FY2009 · CA

BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF

$280,788
Anton Wellstein · Georgetown University · R01 · FY2010 · CA

BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGF

$280,788
Anton Wellstein · Georgetown University · R01 · FY2007 · CA

Role of the mitochondrial RNA polymerase POLRMT in MYC function

$280,780
Steven B McMahon · Thomas Jefferson University · R01 · FY2014 · CA

Senior Leadership

$280,753
Russel E. Kaufman · Wistar Institute · P30 · FY2009 · CA

Photoacoustic detection, capture, and analysis of circulating melanoma cells

$280,721
John A Viator · Duquesne University · R01 · FY2017 · CA

Photoacoustic detection, capture, and analysis of circulating melanoma cells

$280,721
John A Viator · Duquesne University · R01 · FY2018 · CA

Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression

$280,670
Donnele Daley · University Of Michigan At Ann Arbor · K08 · FY2023 · CA

Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression

$280,670
Donnele Daley · University Of Michigan At Ann Arbor · K08 · FY2025 · CA

Microbial Dysbiosis in Pancreatic Cancer Initiation and Progression

$280,670
Donnele Daley · University Of Michigan At Ann Arbor · K08 · FY2024 · CA

TGFbeta IN THE BONE MICROENVIRONMENT: ROLE IN TUMOR METASTASIS

$280,643
Theresa A Guise · Indiana University Indianapolis · R01 · FY2010 · CA

Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma

$280,592
Rhona N Stein · Ctr For Molecular Medicine/Immunology · R01 · FY2006 · CA

RETINOIC ACID RECEPTOR GAMMA SPECIFIC SIGNALING IN MELAN

$280,489
Boston University Medical Campus · R01 · FY2002 · CA

Animal Model for Her-2/neu Specific TCR Gene Transfer

$280,412
Michael I Nishimura · Medical University Of South Carolina · R01 · FY2006 · CA

Core 1: Administrative Core

$280,406
Marcus W Bosenberg · Yale University · P50 · FY2022 · CA

GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY

$280,350
James W. Young · Sloan-Kettering Inst Can Research · R01 · FY2011 · CA

Inhibitors in Src Signaling for Antitumor Therapy

$280,320
Richard Jove · Beckman Research Institute/City Of Hope · R01 · FY2011 · CA

Project 1

$280,289
Kunle O Odunsi · Roswell Park Cancer Institute Corp · P50 · FY2024 · CA

PERTURBATION OF HYALURONAN FUNCTION IN CANCER

$280,254
Tufts University Boston · R01 · FY2002 · CA

POLYVALENT VACCINE--PHASE III TRIAL IN STAGE IV MELANOMA

$280,245
John Wayne Cancer Institute · R01 · FY2001 · CA

Animal Model for Her-2/neu Specific TCR Gene Transfer

$280,188
University Of Chicago · R01 · FY2005 · CA

Control of cancer and metastasis by endothelial-derived epoxyeicosatrienoic acids

$280,175
Dipak Panigrahy · Boston Children'S Hospital · R01 · FY2012 · CA

ROLE OF THE P34CDC2 RELATED PITSLRE PROTEIN KINASES

$280,157
University Of Arizona · R01 · FY2003 · CA